



Biochemical Pharmacology, Volume 80, issue 3, 1 August 2010

Contents


COMMENTARY

Urocortins in heart failure

289–296

Sowmya Venkatasubramanian, David E. Newby, Ninian N. Lang


The effects of urocortins on multiple organ systems in heart failure: Urocortins, through different mechanisms exerts a multitude of beneficial effects on the various organ systems as demonstrated by animal and human models. ACTH: adrenocorticotrophic hormone; Ucn 1: urocortin 1; LAP: left atrial pressure; BP: blood pressure; PRA: plasma renin activity.



Clinical utility of calcimimetics targeting the extracellular calcium-sensing receptor (CaSR)

297–307

Edward M. Brown




ANTIBIOTICS AND CHEMOTHERAPEUTICS

Metabolism of short-chain ceramide by human cancer cells—Implications for therapeutic approaches

308–315


Jacqueline V. Chapman, Valérie Gouazé-Andersson, Maria C. Messner, Margaret Flowers, Ramin Karimi, Mark Kester, Brian M. Barth, Xin Liu, Yong-Yu Liu, Armando E. Giuliano, Myles C. Cabot



Ferritin H induction by histone deacetylase inhibitors

316–324


Wei Wang, Xiumin Di, Suzy V. Torti, Frank M. Torti



Transcriptional up-regulation of SOD1 by CEBPD: A potential target for cisplatin resistant human urothelial carcinoma cells

325–334

Tzyh-Chyuan Hour, Yan-Liang Lai, Ching-I Kuan, Chen-Kung Chou, Ju-Ming Wang, Huang-Yao Tu, Huei-Ting Hu, Chang-Shen Lin, Wen-Jeng Wu, Yeong-Shiau Pu, Esta Sterneck, A-Mei Huang




The NER proteins XPC and CSB, but not ERCC1, regulate the sensitivity to the novel DNA binder S23906: Implications for recognition and repair of antitumor alkylators

335–343

Céline J. Rocca, Virginie Poindessous, Daniele G. Soares, Karima El Ouadrani, Alain Sarasin, Eric Guérin, Aimery de Gramont, João A.P. Henriques, Alexandre E. Escargueil, Annette K. Larsen


Cells resistant to S23906, a bulky monofunctional agent (left) show increased nucleotide excision repair activity (middle) which is accompanied by increased expression of CSB, XPC, but not ERCC1 (right).



Mechanistic insights into antitumor effects of new dinuclear *cis* Pt^{II} complexes containing aromatic linkers

344–351


Lenka Zerzankova, Hana Kosthunova, Marie Vojtiskova, Olga Novakova, Tereza Suchankova, Miaoxin Lin, Zijian Guo, Jana Kasparkova, Viktor Brabec



Alisol-B, a novel phyto-steroid, suppresses the RANKL-induced osteoclast formation and prevents bone loss in mice

352–361

Ji-Won Lee, Yasuhiro Kobayashi, Yuko Nakamichi, Nobuyuki Udagawa, Naoyuki Takahashi, Nam-Kyung Im, Hwa-Jeong Seo, Won Bae Jeon, Takayuki Yonezawa, Byung-Yoon Cha, Je-Tae Woo




Altered phospholipid transfer protein gene expression and serum lipid profile by topotecan

362–369

Rudel A. Saunders, Kazuyuki Fujii, Leah Alabanza, Roald Ravatn, Tsunekazu Kita, Kazuya Kudoh, Masahiro Oka, Khew-Voon Chin

Induction of PLTP gene expression by topoisomerase I poisons and its implication as a biomarker for the development of drug-induced pancreatitis



Rimonabant-induced apoptosis in leukemia cell lines: Activation of caspase-dependent and -independent pathways

370–380

Dario Gallotta, Patrizia Nigro, Roberta Cotugno, Patrizia Gazzero, Maurizio Bifulco, Maria Antonietta Belisario

SR141716 induces cell cycle arrest and programmed cell death in leukemia-derived Jurkat and U937 cell lines, and, depending on the cell type, activates different as well equivalent death pathways to a different extent. SR141716 exhibits low toxicity in PBMC.




CARDIOVASCULAR PHARMACOLOGY

The structure of the C-terminal helical bundle in glutathione transferase M2-2 determines its ability to inhibit the cardiac ryanodine receptor

381–388

Ruwani Hewawasam, Dan Liu, Marco G. Casarotto, Angela F. Dulhunty, Philip G. Board


Ca²⁺ release through cardiac ryanodine receptors is inhibited by the carboxy terminal domain of glutathione transferase M2-2. Therapeutics mimicking this structure may reduce excess Ca²⁺ release that occurs in arrhythmia.



INFLAMMATION AND IMMUNOPHARMACOLOGY

The anionic amphiphile SDS is an antagonist for the human neutrophil formyl peptide receptor 1 389–395

Fredrik B. Thorén, Jennie Karlsson, Claes Dahlgren, Huamei Forsman




METABOLIC DISORDERS AND ENDOCRINOLOGY

Effects of γ -glutamyl linker on DPP-IV resistance, duration of action and biological efficacy of acylated glucagon-like peptide-1 396–401

Barry D. Kerr, Peter R. Flatt, Victor A. Gault


Omission of the γ -glutamyl linker in Liraglutide does not affect insulin secretion and glucose homeostasis in obesity-diabetes



NEUROPHARMACOLOGY

Repeated nicotine administration robustly increases bPiDDB inhibitory potency at $\alpha 6\beta 2$ -containing nicotinic receptors mediating nicotine-evoked dopamine release 402–409

Andrew M. Smith, Marharyta Pivavarchyk, Thomas E. Wooters, Zhenfa Zhang, Guangrong Zheng, J. Michael McIntosh, Peter A. Crooks, Michael T. Bardo, Linda P. Dwoskin




TOXICOLOGY

Differential effect of covalent protein modification and glutathione depletion on the transcriptional response of Nrf2 and NF- κ B 410–421

Alvin J.L. Chia, Christopher E. Goldring, Neil R. Kitteringham, Shi Quan Wong, Paul Morgan, B. Kevin Park

CRMs activate Nrf2, but inhibit NF- κ B, and GSH depletion without covalent modification activates both Nrf2 and NF- κ B. This leads to cellular protection against the potentially harmful effects of redox perturbation.



INDEXED/ABSTRACTED IN: *Curr. Cont. ASCA*, *Biosis Data*, *CAB Inter.*, *Chemical Abstracts Service*, *Curr. Cont./Life Sci.*, *CABS*, *EMBASE/Excerpt. Med.*, *Curr. Cont. ISI/BIOMED Database*, *MEDLINE*, *PASCAL-CNRS Data*, *Curr. Cont. Sci. Cit. Ind.*, *Curr. Cont. SCISEARCH Data*, *Ind. Med.*, *Reference Update*. Also covered in the abstract and citation database SCOPUS®. Full text available on ScienceDirect®.



ELSEVIER

Available online at www.sciencedirect.com



ScienceDirect

www.elsevier.com/locate/biochempharm